Semaglutide patent expiry timing varies sharply by country. India's composition patent lapsed March 20, 2026, triggering 26+ branded generics from 13 companies at prices as low as $14/month. Canada became the first G7 country with approved generics on April 28 (Dr. Reddy's) and May 1 (Apotex), with Sandoz targeting Q3 2026 commercial launch and seven additional submissions in Health Canada review. Brazil, China, Turkey and seven other countries cover 40% of the global population and 48% of the global obesity burden — all with patent timing through 2026 or 2027.
A March 2026 medRxiv preprint from the University of Liverpool priced generic injectable semaglutide production at $28-140/person-year and oral formulations at $186-380/person-year, projecting 84% of the global obesity burden could be reached by end-2026 if device patents and policy coordination cooperate. The catch in the US specifically is the December 2031 composition-of-matter patent cliff plus a 57% device-patent share that could complicate pen-injector generic entry. Novo Nordisk's preemptive ~50% list-price cut to roughly $675/month effective January 2027 is the clearest defensive signal.
Stories here cover patent timing, generic approvals, Novo's pricing response, cross-border purchase considerations, and the broader equitable-access conversation that the Lancet and IQVIA have been driving. See #semaglutide, #patent-expiry, and #health-canada.
Sandoz Group AG's preparations for a Q3 2026 Canadian commercial launch of generic semaglutide came into sharper focus over the weekend as Health Canada continues reviewing seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals. Sandoz signaled in late 2024 it would launch a Canadian generic semaglutide in 2026 when the active-drug patent expired; the company's filing is currently under Health Canada review with commercial readiness contingent on the agency's review timeline. Industry analysts expect Sandoz to enter the Canadian market with pricing 45-90% below the brand Ozempic CAD $300-400/month range, putting Sandoz generic pricing in the CAD $30-200/month tier (~$22-145 USD/month). The Canadian generic market is a five-year preview of what will hit the US after December 2031 patent expiry; watch what Ontario, BC, and Quebec formulary committees decide on listing terms over the next 90 days.
The Lancet's 'Making Treatment for Obesity More Equitable' editorial (March 2026) and an accompanying medRxiv preprint (Hill et al., March 4, 2026) synthesized 2024-2025 active pharmaceutical ingredient shipment data to estimate generic semaglutide production costs at $28-140/person-year for injectable formulations and $186-380/person-year for oral formulations. By the end of 2026, generic injectable semaglutide could be available in 160 countries covering 69% of global T2DM and 84% of clinical obesity. The 10 countries where Novo Nordisk's 2026 patents expired represent 44% of the global population and 48% of the global obesity burden — including Brazil, Canada, China, India, and Turkey. The constraint isn't manufacturing economics; it's device-patent thickets (57% of analyzed semaglutide patents are device patents) and policy coordination (pooled procurement, voluntary licensing, tiered pricing).
Health Canada announced May 1 approval of a second generic semaglutide injection, filed by Canadian-based Apotex as a generic version of Novo Nordisk's Ozempic. The April 28, 2026 first approval (Dr. Reddy's Laboratories) was followed three days later by the Apotex green light, making Canada the first G7 country with two approved generic semaglutide products. Health Canada is currently reviewing seven additional generic submissions. Patent context: Canadian patent protection lapsed earlier than expected after a Novo Nordisk maintenance-fee issue. Sandoz separately targets a Q3 2026 commercial launch and the company has projected 45-90% price reductions versus brand-name Ozempic. US patent protection runs through December 2031.